Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharamaceutical compositions for treating chronic pain and pain associated with neuropathy

a technology of pharamaceuticals and compositions, applied in the direction of drug compositions, peptide/protein ingredients, nervous disorders, etc., can solve the problems of not being able to fully understand the pathophysiology of chronic pain, not being able to eliminate having little or no toxicity and/or harmful side effects. , to achieve the effect of avoiding side effects, and eliminating the majority of pain

Inactive Publication Date: 2020-01-02
SINGH CHANDRA ULAGARAJ
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a new way to treat pain. It involves combining low dosages of an NMDA antagonist, a type of opioid, and an anticonvulsant. This combination works better than traditional therapies for certain types of pain, like fibromyalgia, diabetic neuropathy, and cancer-related pain. The new method has less toxicity and side effects, which makes it safer and more effective.

Problems solved by technology

Chronic pain is a common problem that presents a major challenge to healthcare providers because of its complex natural history, unclear etiology, and poor response to therapy.
The pathophysiology of chronic pain is multifactorial and complex and still is poorly understood.
Unfortunately, several adverse side effects are associated with the drugs provided at the above dosages.
All opiates have side effects, of which the most dangerous are respiratory and cardiovascular depression associated with excessive sedation.
NSAIDs may also induce side effects such as exacerbation of bleeding tendencies and the impairment renal function.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharamaceutical compositions for treating chronic pain and pain associated with neuropathy
  • Pharamaceutical compositions for treating chronic pain and pain associated with neuropathy
  • Pharamaceutical compositions for treating chronic pain and pain associated with neuropathy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Capsule Formulation Containing Gabapentin

[0280]The following ingredients in each one of the capsule formulations were weighed accurately, ground using a pestle and mortar to fine and homogeneous powders. These powders were sieved through 100 mesh and filled into hard gelatin capsules. The composition of each capsule formulation is listed below.

CAPSULE FORMULATION 1In eachIn 100Tramadol Hydrochloride39.8mg3.98gDextromethorphan51.0mg5.10gHydrochlorideGabapentin90.0mg9.00gMicrocrystalline Cellulose27.6mg2.76gSodium Lauryl Sulfate1.6mg0.16gTotal Solid210mg21.0g

CAPSULE FORMULATION 2In eachIn 100Tramadol Hydrochloride39.8mg3.98gDextromethorphan51.0mg5.10gHydrochlorideGabapentin180.0mg18.00gMicrocrystalline Cellulose77.4mg7.74gSodium Lauryl Sulfate1.6mg0.16gTotal Solid350mg35.0g

CAPSULE FORMULATION 3In eachIn 100Tramadol Hydrochloride35.0mg3.50gDextromethorphan45.0mg4.50gHydrochlorideGabapentin90.0mg9.00gMicrocrystalline Cellulose36.5mg3.65gSodium Lauryl Sulfate2.0mg0.20gTalc1.5mg0.15gTotal...

example 2

Capsule Formulation Containing Pregabalin

[0281]The following ingredients in each one of the capsule formulations were weighed accurately, ground using a pestle and mortar to fine and homogeneous powders. These powders were sieved through 100 mesh and filled into hard gelatin capsules. The composition of each capsule formulation is listed below.

CAPSULE FORMULATION 1In eachIn 100Tramadol Hydrochloride39.8mg3.98gDextromethorphan51.0mg5.10gHydrochloridePregabalin15.0mg1.50gMicrocrystalline Cellulose102.6mg10.26gSodium Lauryl Sulfate1.6mg0.16gTotal Solid210mg21.0g

CAPSULE FORMULATION 2In eachIn 100Tramadol Hydrochloride39.8mg3.98gDextromethorphan51.0mg5.10gHydrochloridePregabalin30.0mg3.00gMicrocrystalline Cellulose87.6mg8.76gSodium Lauryl Sulfate1.6mg0.16gTotal Solid210mg21.0g

CAPSULE FORMULATION 3In eachIn 100Tramadol Hydrochloride35.0mg3.50gDextromethorphan45.0mg4.50gHydrochloridePregabalin20.0mg2.00gMicrocrystalline Cellulose106.5mg10.65gSodium Lauryl Sulfate2.0mg0.20gTalc1.5mg0.15gTot...

example 3

Capsule Formulation Containing Amitriptyline

[0282]The following ingredients in each one of the capsule formulations were weighed accurately, ground using a pestle and mortar to fine and homogeneous powders. These powders were sieved through 100 mesh and filled into hard gelatin capsules. The composition of each capsule formulation is listed below.

CAPSULE FORMULATION 1In eachIn 100Tramadol Hydrochloride39.8mg3.98gDextromethorphan51.0mg5.10gHydrochlorideAmitriptyline Hydrochloride11.4mg11.40gMicrocrystalline Cellulose106.2mg106.2gSodium Lauryl Sulfate1.6mg0.16gTotal Solid210mg21.0g

CAPSULE FORMULATION 2In eachIn 100Tramadol Hydrochloride39.8mg3.98gDextromethorphan51.0mg5.10gHydrochlorideAmitriptyline Hydrochloride5.7mg5.70gMicrocrystalline Cellulose111.9mg11.19gSodium Lauryl Sulfate1.6mg0.16gTotal Solid210mg21.0g

CAPSLUE FORMULATION 3In eachIn 100Tramadol Hydrochloride35.0mg3.50gDextromethorphan45.0mg4.50gHydrochlorideAmitriptyline Hydrochloride11.4mg1.14gMicrocrystalline Cellulose115.1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pharmaceutical compositionaaaaaaaaaa
healing timeaaaaaaaaaa
compositionsaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods and compositions for the treatment of neuropathic pain. In certain embodiments, compositions comprising an dextromethorphan (or other N-methyl-D-aspartate receptor antagonist), tramadol, and gabapentin can synergistically act to reduce pain in a human patient. Pharmaceutical compositions may also comprise a capsaicinoid, an esterified capsaicinoid, and / or a tricyclic antidepressant.

Description

[0001]This application claims priority to U.S. Application No. 60 / 954,251 filed on Aug. 6, 2007, the entire disclosure of which is specifically incorporated herein by reference in its entirety without disclaimer.BACKGROUND OF THE INVENTION[0002]Chronic pain is a common problem that presents a major challenge to healthcare providers because of its complex natural history, unclear etiology, and poor response to therapy. Chronic pain is a poorly defined condition, and opinions vary regarding which duration qualifies a pain as chronic. Most clinicians consider ongoing pain lasting longer than 6 months as diagnostic, and others have used 3 months as the minimum criterion. In chronic pain, the duration parameter is used arbitrarily; some authors suggest that any pain that persists longer than the reasonable expected healing time for the involved tissues should be considered chronic pain. The pathophysiology of chronic pain is multifactorial and complex and still is poorly understood. Some...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/195A61K31/137A61K31/485A61K31/5377
CPCA61K31/485A61K31/137A61K31/5377A61K31/195A61P25/04A61P29/00A61K2300/00
Inventor SINGH, CHANDRA ULAGARAJ
Owner SINGH CHANDRA ULAGARAJ
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products